Lucid Diagnostics

About:

Lucid Diagnostics develops a non-invasive, office based diagnostic test for biomarkers to esophageal cancer.

Website: http://www.luciddx.com

Twitter/X: LucidDiag

Description:

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Total Funding Amount:

$30.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2018-05-30

Contact Email:

info(AT)luciddx.com

Founders:

Shaun O'Neil

Number of Employees:

51-100

Last Funding Date:

2024-05-07

IPO Status:

Public

Industries:

© 2025 bioDAO.ai